Endonovo Therapeutics, Inc. (ENDV) stock
ENDVOTCElectromedical & Electrotherapeutic ApparatusFiscal year ends December 31
Financials through Q3 FY2023, quarter ended Sep 30, 2023Last filing: 10-Q/A on Dec 29, 2023
$0.00+0.00 (0.00%)
Close on Oct 19, 2026Market cap $135.08KP/E –Yield –
Endonovo Therapeutics net income
Net income is the profit left for shareholders after every expense, interest and tax.
Endonovo Therapeutics's net income for the twelve months ending Sep 30, 2023 was -$4.40M. For fiscal 2022 it was -$18.47M. The highest annual figure on record is -$69.40K in fiscal 2010.
Annual net income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | -$18.47M | – |
| FY2021 | Dec 31, 2021 | -$3.10M | – |
| FY2020 | Dec 31, 2020 | -$395.58K | – |
| FY2019 | Dec 31, 2019 | -$17.31M | – |
| FY2018 | Dec 31, 2018 | -$6.44M | – |
| FY2017 | Dec 31, 2017 | -$10.81M | – |
| FY2016 | Dec 31, 2016 | -$5.32M | – |
| FY2015 | Dec 31, 2015 | -$6.77M | – |
| FY2014 | Dec 31, 2014 | -$959.49K | – |
| FY2013 | Dec 31, 2013 | -$2.89M | – |
| FY2012 | Dec 31, 2012 | -$1.91M | – |
| FY2011 | Dec 31, 2011 | -$94.09K | – |
| FY2010 | Dec 31, 2010 | -$69.40K | – |
Quarterly net income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2023 | Sep 30, 2023 | -$766.17K | – |
| Q2 FY2023 | Jun 30, 2023 | $2.06M | – |
| Q1 FY2023 | Mar 31, 2023 | $7.23M | – |
| Q4 FY2022 | Dec 31, 2022 | -$12.93M | -639.7% |
| Q3 FY2022 | Sep 30, 2022 | -$603.36K | – |
| Q2 FY2022 | Jun 30, 2022 | -$2.53M | – |
| Q1 FY2022 | Mar 31, 2022 | -$2.41M | – |
| Q4 FY2021 | Dec 31, 2021 | $2.40M | – |
| Q3 FY2021 | Sep 30, 2021 | -$1.52M | – |
| Q2 FY2021 | Jun 30, 2021 | -$1.30M | – |
| Q1 FY2021 | Mar 31, 2021 | -$2.68M | -161.8% |
| Q4 FY2020 | Dec 31, 2020 | -$2.03M | – |
| Q3 FY2020 | Sep 30, 2020 | -$1.07M | – |
| Q2 FY2020 | Jun 30, 2020 | -$1.63M | – |
| Q1 FY2020 | Mar 31, 2020 | $4.34M | – |
| Q4 FY2019 | Dec 31, 2019 | -$5.66M | -509.8% |
| Q3 FY2019 | Sep 30, 2019 | -$1.41M | – |
| Q2 FY2019 | Jun 30, 2019 | -$7.84M | – |
| Q1 FY2019 | Mar 31, 2019 | -$2.41M | – |
| Q4 FY2018 | Dec 31, 2018 | $1.38M | -21.9% |
| Q3 FY2018 | Sep 30, 2018 | -$5.95M | – |
| Q2 FY2018 | Jun 30, 2018 | -$1.25M | -167.3% |
| Q1 FY2018 | Mar 31, 2018 | -$618.92K | – |
| Q4 FY2017 | Dec 31, 2017 | $1.77M | – |
| Q3 FY2017 | Sep 30, 2017 | -$6.67M | – |
| Q2 FY2017 | Jun 30, 2017 | $1.86M | – |
| Q1 FY2017 | Mar 31, 2017 | -$7.76M | – |
| Q4 FY2016 | Dec 31, 2016 | -$739.83K | -881.8% |
| Q1 FY2016 | Jun 30, 2016 | -$2.36M | – |
| Q1 FY2015 | Mar 31, 2015 | -$480.16K | – |
| Q4 FY2014 | Dec 31, 2014 | -$222.93K | – |
| Q3 FY2014 | Sep 30, 2014 | $94.63K | – |
| Q2 FY2014 | Jun 30, 2014 | -$202.68K | – |
| Q1 FY2014 | Mar 31, 2014 | -$628.52K | – |
| Q4 FY2013 | Dec 31, 2013 | -$674.45K | – |
| Q3 FY2013 | Sep 30, 2013 | -$452.40K | – |
| Q2 FY2013 | Jun 30, 2013 | -$639.99K | – |
| Q1 FY2013 | Mar 31, 2013 | -$1.13M | – |
See a number that looks wrong?